Stryker Corporation $SYK Shares Sold by Greenleaf Trust

Key Points

• Greenleaf Trust reduced its Stryker stake by 0.5%, selling 72,612 shares but retaining 15.16 million shares worth approximately $4.17 billion. Stryker remains the trust’s largest holding and represents 42.8% of its portfolio.
• Stryker’s third-quarter results exceeded the prior year but missed analyst expectations, with revenue up 7.6% to $6.52 billion and EPS of $3.52 versus estimates of $6.62 billion and $3.55, respectively.
• The company lowered its 2026 outlook amid weaker joint-replacement demand and supply issues, while analysts remain divided; the stock carries a “Moderate Buy” consensus rating and a $355.84 average price target.

Greenleaf Trust trimmed its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 0.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,155,933 shares of the medical technology company's stock after selling 72,612 shares during the period. Stryker accounts for approximately 42.8% of Greenleaf Trust's investment portfolio, making the stock its biggest position. Greenleaf Trust owned approximately 3.95% of Stryker worth $4,173,792,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. MeadowBrook Investment Advisors LLC grew its position in shares of Stryker by 4.4% in the third quarter. MeadowBrook Investment Advisors LLC now owns 5,259 shares of the medical technology company's stock valued at $1,448,000 after purchasing an additional 224 shares during the last quarter. Columbia Bank lifted its holdings in shares of Stryker by 14.8% during the third quarter. Columbia Bank now owns 8,576 shares of the medical technology company's stock worth $2,362,000 after buying an additional 1,106 shares in the last quarter. Hoey Investments Inc. boosted its holdings in Stryker by 31.4% in the 3rd quarter. Hoey Investments Inc. now owns 469 shares of the medical technology company's stock valued at $129,000 after purchasing an additional 112 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Stryker by 3.5% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 767,516 shares of the medical technology company's stock valued at $211,366,000 after buying an additional 26,311 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Stryker during the 3rd quarter valued at $25,964,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Stryker

In other Stryker news, insider Dylan Crotty sold 441 shares of the firm's stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider directly owned 6,102 shares of the company's stock, valued at $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Ronda Stryker sold 300,000 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 351,267 shares of company stock valued at $118,197,701. Company insiders own 4.60% of the company's stock.

Stryker Stock Down 0.1%

Stryker stock opened at $291.56 on Monday. Stryker Corporation has a fifty-two week low of $267.00 and a fifty-two week high of $389.33. The firm's 50-day simple moving average is $292.83 and its 200 day simple moving average is $324.51. The stock has a market cap of $111.83 billion, a PE ratio of 31.05, a price-to-earnings-growth ratio of 1.89 and a beta of 0.78. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 2.18.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.55 by ($0.03). The business had revenue of $6.52 billion during the quarter, compared to the consensus estimate of $6.62 billion. Stryker had a net margin of 13.78% and a return on equity of 23.74%. The business's revenue was up 7.6% on a year-over-year basis. During the same period in the prior year, the company earned $3.19 earnings per share. Research analysts predict that Stryker Corporation will post 14.85 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend was Wednesday, September 30th. Stryker's dividend payout ratio is currently 37.49%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SYK. UBS Group assumed coverage on shares of Stryker in a report on Tuesday, July 28th. They set a "buy" rating and a $400.00 price target for the company. Johnson Rice lowered shares of Stryker to a "hold" rating in a report on Friday. Wells Fargo & Company lowered their target price on Stryker from $418.00 to $348.00 and set an "overweight" rating for the company in a research report on Wednesday, September 9th. Citizens Jmp dropped their price target on shares of Stryker from $400.00 to $390.00 and set a "market outperform" rating on the stock in a research report on Friday. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Stryker in a research note on Thursday. Sixteen equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $355.84.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

About Stryker

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company's product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.